“RESEARCH FOR A LIFE WITHOUT CANCER” IS OUR MISSION AT THE GERMAN CANCER RESEARCH CENTER. WE INVESTIGATE HOW CANCER DEVELOPS, IDENTIFY CANCER RISK FACTORS AND LOOK FOR NEW CANCER PREVENTION STRATEGIES. WE DEVELOP NEW METHODS WITH WHICH TUMORS CAN BE DIAGNOSED MORE PRECISELY AND CANCER PATIENTS CAN BE TREATED MORE SUCCESSFULLY. EVERY CONTRIBUTION COUNTS – WHETHER IN RESEARCH, ADMINISTRATION OR INFRASTRUCTURE. THIS IS WHAT MAKES OUR DAILY WORK SO MEANINGFUL AND EXCITING.

The Helmholtz Institute HI-TRON in Mainz is a collaboration of the German Cancer Research Center (DKFZ) with the Johannes Gutenberg-University (JGU), the University Medicine Mainz (UM Mainz) and the non-profit TRON gGmbH (TRON). The aim of the partnership is to develop pioneering immunotherapies and identify new biomarkers for the effectiveness of the treatment.
The Division “mRNA Cancer Immunotherapies” at HI-TRON Mainz headed by Prof. Dr. Uğur Şahin focuses on improving cancer immunotherapies by addressing resistance mechanisms and limited patient responses. We integrate multi-omics data to identify novel biomarkers and therapeutic targets, and develop mRNA-based strategies to enhance anti-tumor immunity. Our work combines RNA-lipid nanoparticle delivery, advanced immune profiling, and physiologically relevant tumor models to accelerate translation from bench to bedside.
To strengthen our international scientific team, we are seeking for the next possible date a highly motivated and enthusiastic

PROJECT DESCRIPTION:

The project aims to manipulate the immune landscape of tumors by delivering targeted mRNA combinations to specific cell populations within the tumor microenvironment (TME), with the goal of enhancing immune activation and overcoming immunosuppressive barriers.

• Design and execute combinatorial mRNA delivery strategies targeting immune, stromal and cancer components of the TME
• Employ RNA-lipid nanoparticle systems for spatially controlled gene expression
• Conduct deep phenotyping of cells in tissues using high-parameter flow cytometry and multiplex 3D imaging
• Use advanced in vitro and ex vivo tumor models to validate therapeutic efficacy
• Collaborate closely with experimental and clinical colleagues from Mainz and Heidelberg
• Present findings in internal meetings and scientific conferences, and contribute to manuscript preparation